[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-31345":3,"doc-seo-31345":27},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"file_id":15,"file_url":16,"file_type":17,"file_size":18,"view_count":4,"is_deleted":4,"is_public":19,"is_downloadable":19,"audit_status":19,"page_count":20,"language":21,"language_code":22,"table_of_contents":23,"faqs":24,"seo_title":13,"seo_description":14,"update_tm":25,"read_time":26},31345,1374391974564,"Clementine","https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002",7,"Healthcare","Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","Dulaglutide, a GLP-1 receptor agonist, was evaluated for effects on major adverse cardiovascular events when added to existing antihyperglycaemic regimens in type 2 diabetes patients with and without prior cardiovascular disease, across a broad range of glycaemic control. In a multicentre, randomized, double-blind, placebo-controlled trial, weekly dulaglutide (1.5 mg) was compared with placebo for a median 5.4 years, showing reduced composite cardiovascular outcomes but no significant difference in all-cause mortality.","cbCairTlf7ept8qp","https://ap.wps.com/l/cbCairTlf7ept8qp","pdf",594682,1,10,"English","en","# Summary\n## Background\n## Methods\n## Findings\n## Interpretation\n# Introduction","[{\"question\":\"What was the main purpose of the REWIND trial?\",\"answer\":\"To assess how the GLP-1 receptor agonist dulaglutide affects major adverse cardiovascular events when added to existing diabetes treatments in people with type 2 diabetes with and without previous cardiovascular disease.\"},{\"question\":\"Who participated and how was the study conducted?\",\"answer\":\"Men and women aged at least 50 with type 2 diabetes and either prior cardiovascular events or cardiovascular risk factors were randomized 1:1 to weekly dulaglutide 1.5 mg or placebo in a multicentre, randomized, double-blind, placebo-controlled design.\"},{\"question\":\"What were the key results for cardiovascular outcomes and mortality?\",\"answer\":\"The primary composite cardiovascular outcome occurred in 12.0% with dulaglutide vs 13.4% with placebo (HR 0.88; p=0.026). All-cause mortality was 10.8% vs 12.0% (HR 0.90; p=0.067), which was not statistically significant.\"}]",1779310972,25,{"code":4,"msg":28,"data":29},"ok",{"site_id":30,"language":22,"slug":31,"title":13,"keywords":32,"description":14,"schema_data":33,"social_meta":84,"head_meta":86,"extra_data":88,"updated_unix":25},105,"dulaglutide-and-cardiovascular-outcomes-in-type-2-diabetes-rewind-a-double-blind-randomised-placebo-controlled-trial","",{"@graph":34,"@context":83},[35,52,66],{"@type":36,"itemListElement":37},"BreadcrumbList",[38,42,46,49],{"item":39,"name":40,"@type":41,"position":19},"https://docshare.wps.com","Home","ListItem",{"item":43,"name":44,"@type":41,"position":45},"https://docshare.wps.com/document/","Document",2,{"item":47,"name":12,"@type":41,"position":48},"https://docshare.wps.com/document/healthcare/",3,{"item":50,"name":13,"@type":41,"position":51},"https://docshare.wps.com/document/dulaglutide-and-cardiovascular-outcomes-in-type-2-diabetes-rewind-a-double-blind-randomised-placebo-controlled-trial/31345/",4,{"url":50,"name":13,"@type":53,"author":54,"headline":13,"publisher":56,"fileFormat":59,"description":14,"dateModified":60,"datePublished":60,"encodingFormat":59,"isAccessibleForFree":61,"interactionStatistic":62},"DigitalDocument",{"name":9,"@type":55},"Person",{"url":39,"name":57,"@type":58},"DocShare","Organization","application/pdf","2026-05-20",true,{"@type":63,"interactionType":64,"userInteractionCount":4},"InteractionCounter",{"@type":65},"ViewAction",{"@type":67,"mainEntity":68},"FAQPage",[69,75,79],{"name":70,"@type":71,"acceptedAnswer":72},"What was the main purpose of the REWIND trial?","Question",{"text":73,"@type":74},"To assess how the GLP-1 receptor agonist dulaglutide affects major adverse cardiovascular events when added to existing diabetes treatments in people with type 2 diabetes with and without previous cardiovascular disease.","Answer",{"name":76,"@type":71,"acceptedAnswer":77},"Who participated and how was the study conducted?",{"text":78,"@type":74},"Men and women aged at least 50 with type 2 diabetes and either prior cardiovascular events or cardiovascular risk factors were randomized 1:1 to weekly dulaglutide 1.5 mg or placebo in a multicentre, randomized, double-blind, placebo-controlled design.",{"name":80,"@type":71,"acceptedAnswer":81},"What were the key results for cardiovascular outcomes and mortality?",{"text":82,"@type":74},"The primary composite cardiovascular outcome occurred in 12.0% with dulaglutide vs 13.4% with placebo (HR 0.88; p=0.026). All-cause mortality was 10.8% vs 12.0% (HR 0.90; p=0.067), which was not statistically significant.","https://schema.org",{"og:url":50,"og:type":85,"og:title":13,"og:site_name":57,"og:description":14},"article",{"robots":87,"canonical":50},"index,follow",{"doc_id":7,"site_id":30}]